Basilea Pharmaceutica (OTCMKTS:BPMUF) Shares Gap Up – What’s Next?

Basilea Pharmaceutica AG (OTCMKTS:BPMUF)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $63.25, but opened at $68.95. Basilea Pharmaceutica shares last traded at $68.95, with a volume of 10 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Basilea Pharmaceutica to a “hold” rating in a research note on Wednesday, September 24th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Basilea Pharmaceutica Trading Down 4.4%

The stock’s 50-day simple moving average is $61.43 and its 200-day simple moving average is $63.86. The company has a current ratio of 6.32, a quick ratio of 5.67 and a debt-to-equity ratio of 0.79.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.